Takaki Yoshikawa

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer

Jakob Nikolas Kather, Alexander T. Pearson, Niels Halama et al. · Nature Medicine · 2019 · 1.4K citations · Full text

Medicine, Genetics, Oncology +16

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial

Kazumasa Fujitani, Han‐Kwang Yang, Junki Mizusawa et al. · The Lancet Oncology · 2016 · 700 citations

Medicine, Oncology, Surgery +12

Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912

Hitoshi Katai, Junki Mizusawa, Hiroshi Katayama et al. · Gastric Cancer · 2016 · 391 citations · Full text

Medicine, Oncology, Surgery +16

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi et al. · Journal of Clinical Oncology · 2019 · 389 citations · Full text

Medicine, Oncology, Pharmacotherapy +17